Fragment-based drug discovery (FBDD)

The Monash Fragment Platform (MFP) provides academic and commercial researchers with access to fragment-based drug discovery (FBDD) technologies for their therapeutic targets. We can provide seamless access to this in-house world-class facility. Find out more about them through Monash Fragment Platform (MFP).

Fragment ligands can feed directly into ATMCF for optimisation towards lead series, then pre-clinical and clinical candidates.